These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144 [TBL] [Abstract][Full Text] [Related]
25. [Maxillofacial location of Burkitt's lymphoma in children treated at the University Hospital Center in Bamako, Mali: a 24-case series]. Togo B; Keita M; Medefo D; Traore F; Sidibe T Med Trop (Mars); 2008 Dec; 68(6):600-2. PubMed ID: 19639827 [TBL] [Abstract][Full Text] [Related]
26. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood. Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717 [TBL] [Abstract][Full Text] [Related]
27. Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma. Hesseling PB; Molyneux E; Kamiza S; Broadhead R Trans R Soc Trop Med Hyg; 2008 Jun; 102(6):602-7. PubMed ID: 18417177 [TBL] [Abstract][Full Text] [Related]
28. [Non-Hodgkinś lymphoma in childhood, preliminary results of the LSA2 L2 protocol modified by high-dose methotrexate]. Prats Viñas J; Gallego Melcón S; Pérez Payarols J; Macía Martí J; Sánchez de Toledo J An Esp Pediatr; 1987 Jan; 26(1):15-21. PubMed ID: 3826937 [TBL] [Abstract][Full Text] [Related]
29. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664 [TBL] [Abstract][Full Text] [Related]
30. [Long-lasting remission of Burkitt's disease in African children. Apropos of 6 cases]. Plo JK; Rain JD; Andoh J; Tea DN; Essoh NP Med Trop (Mars); 1986; 46(2):141-6. PubMed ID: 3724411 [TBL] [Abstract][Full Text] [Related]
31. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Diviné M; Casassus P; Koscielny S; Bosq J; Sebban C; Le Maignan C; Stamattoulas A; Dupriez B; Raphaël M; Pico JL; Ribrag V; ; Ann Oncol; 2005 Dec; 16(12):1928-35. PubMed ID: 16284057 [TBL] [Abstract][Full Text] [Related]
32. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Soussain C; Patte C; Ostronoff M; Delmer A; Rigal-Huguet F; Cambier N; Leprisé PY; François S; Cony-Makhoul P; Harousseau JL Blood; 1995 Feb; 85(3):664-74. PubMed ID: 7833470 [TBL] [Abstract][Full Text] [Related]
33. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060 [TBL] [Abstract][Full Text] [Related]
34. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Todeschini G; Tecchio C; Degani D; Meneghini V; Marradi P; Balter R; Zanotti R; Ricetti M; Franchini M; Perona G Ann Oncol; 1997; 8 Suppl 1():77-81. PubMed ID: 9187436 [TBL] [Abstract][Full Text] [Related]
35. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma]. Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711 [TBL] [Abstract][Full Text] [Related]
36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
37. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819 [TBL] [Abstract][Full Text] [Related]
38. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Di Nicola M; Carlo-Stella C; Mariotti J; Devizzi L; Massimino M; Cabras A; Magni M; Matteucci P; Guidetti A; Gandola L; Gianni AM Br J Haematol; 2004 Sep; 126(6):815-20. PubMed ID: 15352985 [TBL] [Abstract][Full Text] [Related]
39. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387 [TBL] [Abstract][Full Text] [Related]